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ABSTRACT 
Although solubility-pH data for desipramine hydrochloride (DsHCl) have been reported 
previously, the aim of the present study was to critically examine the aqueous solubility-pH behavior of 
DsHCl in buffer-free and buffered solutions, in the presence of physiologically-relevant chloride 
concentration, using experimental practices recommended in the recently-published “white paper” 
(Avdeef et al., 2016). The computer program pDISOL-X was used to design the structured experiments 
(pH-RSF method), to process the data, and to refine the equilibrium constants. Low-to-high and high-to-
low pH assays (using HCl, H3PO4, or NaOH to adjust pH) were performed on phosphate-buffered 
(0.12-0.15 M) saturated solutions of DsHCl in the pH 1.3-11.6 range. After equilibration (stirring 6 h, 
followed by 18 h stir-free sedimentation), filtration or centrifugation was used for phase separation. 
Concentration was measured using HPLC with UV/VIS detection. The 2:1 drug-phosphate solubility 
product (Ksp
2:1
 = [DsH
+
]
2
[HPO4
2-
]) was determined from data in the pH 4-9 region. The free base of 
desipramine was prepared and used to determine the Ksp
1:1
 ([DsH
+
][H2PO4
-
]) in chloride-free acidified 
suspension. In addition, phosphate-free titrations were conducted to determine the intrinsic solubility, S0, 
and the 1:1 drug-chloride solubility product, Ksp
DsH.Cl 
= [DsH
+
][Cl
-
]. Under the assay conditions, only the 
phosphate-free solutions showed some supersaturation near pHmax 8.0. In phosphate-containing solutions, 
pHmax was indicated at higher pH (8.8-9.6). Oils mixed with solids were observed to form in alkaline 
solutions (pH > 11). Notably, soluble drug-phosphate complexes appeared to form below pH 3.9 and 
above pHmax in saturated phosphate-containing saline solutions. This was indicated by the systematic pH 
shift to higher values in the log S-pH curve in alkaline solution than expected from the Henderson-
Hasselbalch equation. For pH < 3.9, saturated phosphate-containing saline solutions exhibited elevated 
solubility, with drug-hydrochloride as the sole precipitate. Salt solubility products, intrinsic solubility, 
and complexation constants, which rationalized the data, were determined. Elemental, thermogravimetric 
(TGA), differential scanning calorimetric (DSC), and powder X-ray diffraction (PXRD) analyses were 
used to characterize the precipitates isolated from suspensions at different pH. 
 
 
Keywords: desipramine-phosphate complexes; pH effect; buffer effect; solubility product; pH-Ramp 
Shake-Flask method; pDISOL-X. 
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1.  Introduction 
Amphiphilic tricyclic bases, such as dibenzazepines and phenothiazines, are surface-active, 
sparingly-soluble drugs, which can exhibit complicated aqueous solution chemistry. Many of the drugs in 
free-base form have low melting points (Bradley et al., 2018). In highly alkaline solutions, these drugs 
sometimes separate out of solution as oil, with elevated solubility. Surface-active drugs often form 
supersaturated solutions near the salt-to-free-base transition pH (pHmax), where partially-charged 
sub-micellar or micellar aggregates form (Higuchi et al., 1953; Zografi et al., 1964; Zografi and Zarenda, 
1966; Sorby et al., 1966; Green, 1967; Florence and Parfitt, 1971; Attwood et al., 1974; Liu and Hurwitz, 
1977; Bogardus and Blackwood, 1979; Serajuddin and Rosoff, 1984; Serajuddin and Jarowski, 1985; Fini 
et al., 1995; Zhu and Streng, 1996; Attwood et al., 1997; Ledwidge and Corrigan, 1998; Gebauer et al., 
2014).  
The above drugs precipitate over a wide range of pH, forming solids in contact with dissolved 
monomers, and often, also with water-soluble sub-micellar aggregates (e.g., dimers, trimers, and higher-
order oligomers). Attwood et al. (1974) found that distilled water solutions of promazine and 
chlorpromazine hydrochlorides form small micelles in aggregated units of eleven monomers. Zografi and 
Zarenda (1966) noted that a 2-5 μM (below solubility limit) solution prepared from chlorpromazine free 
base (pH 9-12) showed no surface activity. However, a 30 μM hydrochloride solution at pH 9 produced a 
stable supersaturated solution, which partly separated as oil (liquid-liquid phase separation, LLPS) and 
was more soluble than the crystalline free base. The above operationally non-commutative solubility 
behavior may be further influenced by complexation/hydrotropy reactions, depending on the buffer used 
(Shoghi et al., 2013).  
The earliest measurement of the intrinsic solubility (S0) of desipramine appears to be that of 
Green (1967), who reported log S0 = -3.66. More recently, a buffer-free potentiometric method was used 
to determine the intrinsic solubility of desipramine as log S0 = -3.81 (Bergström et al., 2003). Also, both 
the log S0 -3.69 and the pKa 10.28 values were simultaneously determined using the pSOL (Pion Inc.) 
buffer-free method (Avdeef, 2012). A small-scale shake-flask solubility measurement of desipramine 
hydrochloride in the pH range of 1.4 to11.2 in 0.15 M phosphate solution revealed a curve that did not 
adhere to the shape predicted by the simple Henderson-Hasselbalch (HH) equation (Bergström et al., 
2004). When the HH equation was applied to the point at pH 11.2, log S0 = -3.90. On the other hand, a 
sigmoidal fit of the data in the alkaline region suggested log S0 = -3.37. The observed log S-pH slope in 
the diagonal region was reported as -0.6, whereas -1 would have been expected from the HH equation. 
Since the lower inflection in the fitted curve was near pH 7.5, well below the pKa, an alternative model 
based on putative aggregation of the free base indicated log S0 = -6.40 (Avdeef, 2014b), a value very 
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different from those of all the other studies. Solid state characterizations to identify the solids isolated 
from suspensions at various pH were not reported in the above studies. The solution behavior of 
desipramine in phosphate-buffered and unbuffered solutions is evidently complicated and only tentatively 
understood, given the above incongruities.  
The aim of the present study was to critically re-examine the aqueous solubility-pH behavior of 
desipramine hydrochloride (DsHCl) in phosphate-buffered and buffer-free solutions, in the presence of 
physiologically-relevant chloride concentration. Specifically, solubility was measured: (a) using state-of-
the-art experimental design, as recommended in a “white paper” on solubility (Avdeef et al., 2016), 
drawing on expert consensus opinions from researchers in six countries; (b) performing solubility 
titrations in two directions, pH 11.61.3 as well as 1.311.6; (c) using both DsHCl and Ds (free base), as 
starting solids; (d) performing titrations in chloride-containing media, without any phosphate; (e) 
performing the converse measurements (phosphate-containing, chloride-free media); (f) isolating solids at 
critical log S-pH points and performing solid state characterizations using elemental, thermogravimetric, 
differential scanning calorimetric, and powder X-ray diffraction analyses. The recently-developed 
computational methods were applied to determine aggregation and/or complexation constants and 
stoichiometries from solubility-pH data (Avdeef, 2007, 2012; Völgyi et al., 2013; Avdeef, 2014a,b; 
Butcher et al., 2015; Pobudkowska et al., 2016; Takács-Novák et al., 2017). We sought to determine the 
solubility products Ksp
1:1 ([DsH+][H2PO4
-]), Ksp
2:1 ([DsH+]2[HPO4
2-]), Ksp
DsH.Cl ([DsH+][Cl-]), as well as S0. 
We anticipated to find evidence of drug aggregates (e.g., (DsH+)n or (DsH
+.Ds)n) , but instead found drug-
phosphate complexes forming below pH 4 and above pHmax in saturated phosphate-containing saline 
solutions.  
 
2. Materials and methods 
 
2.1 Chemicals and reagents 
Desipramine hydrochloride (DsHCl) and sodium dihydrogen phosphate dihydrate (analytical 
reagent grade) were purchased from Sigma-Aldrich and used as received. Hydrochloric acid and sodium 
hydroxide were purchased from Merck (Titrisol
®
 ampoules). Phosphoric acid (analytical reagent grade) 
was purchased from Fisher Chemical. All solutions were prepared with Millipore-purified water. 
 
2.2 pH measurement 
In all experiments, pH values were measured using Crison pH-Burette 24 2S equipped with a 
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micro-combined pH electrode (Crison pH electrode 50 29). The electrode was calibrated by standard 
Crison buffer solutions (pH 4.01, 7.00, and 9.21). 
 
2.3 HPLC concentration determination 
After equilibration in the solubility experiments, excess solid was removed by filtration or 
centrifugation (cf., Supplementary Material). The concentration of the drug in the supernatant was 
determined by HPLC-UV/VIS system (Agilent Technologies 1260 Infinity LC System). Chromatographic 
separation was conducted using Zorbax Eclipse XDB-C18 50×4.6 mm column with 1.8 µm particles at 
flow rate of 0.5 mL/min. Gradient elution was used: from 70% A + 30% B to 100% B during 5 minutes, 
100% B for 1 minute, and back to 70% A + 30% B during 1 minute (solvent A: water with 1% acetic 
acid; solvent B: acetonitrile). Detection wavelength: 250 nm; column temperature: 25°C.  
 
2.4 Differential scanning calorimetric (DSC) analysis  
Solids isolated from suspensions were analyzed for their thermal behavior as a function of 
temperature using a Q200 differential scanning calorimeter (TA instruments, DE, USA). Samples 
(5-10 mg each) were sealed in Tzero pan with a pinhole for the escape of any volatile material. The 
samples were equilibrated at 5°C for 5 min and then heated at the rate of 10°C/min to the final 
temperature of ~225°C that was above the potential melting points of samples. When heat-cool-heat 
cycles were used, samples were prepared similarly and then initial heating, cooling and reheating were 
conducted at rates of 10, 30 and 3°C; the reheating was done at a lower heating rate to facilitate any 
recrystallization of material. The results were analysed using Universal Analysis software version 2000 
(TA Instruments).  
 
2.5 Thermogravimetric Analysis (TGA)  
Approximately 4-6 mg of samples were analyzed using the TGA Q50 thermogravimetric 
analyzer, (TA instruments, DE, USA). The samples were heated from ~25°C to 300°C at a heating rate of 
10°C/min in a nitrogen environment. 
  
2.6 Powder X-ray diffraction (PXRD) analysis 
A powder X-ray diffractometer (Shimadzu 6000, Kyoto, Japan) was used to obtain PXRD 
patterns at room temperature with a monochromatic CuKα radiation source operated at 40 kV and 30 mA 
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and the scanning rate of 2°/min over the 2θ range of 10° to 60°. The test materials were placed as thin 
layers inside glass sample holders.  
 
2.7 Elemental analysis 
 The elemental analysis was accomplished by combustion analysis on a Vario EL III C,H,N,S/O 
Elemental Analyzer (Elementar Analysensysteme GmbH, Hanau-Germany). 
 
2.8 Solubility determination using the pH-Ramp Shake-Flask (pH-RSF) method 
Before commencing any assays, solubility-pH simulations were performed using the computer 
program pDISOL-X
TM
 (in-ADME Research). This was to plan for the weights of reagents to use 
(including buffers, if suggested), as well as the expected volumes of titrants to add in order to adjust the 
pH to suitable spacing (e.g., 0.2-0.5 units) across the whole pH range of interest. Knowledge of the drug 
pKa value and an in silico estimate of the intrinsic solubility, S0, are essential. Also, in the case of 
phosphate-containing media, drug-phosphate solubility products (Ksp) can be approximated from the S0 
values (Avdeef, 2014b). For other counterions, the sdiff 3-4 approximation (Avdeef et al., 2000) may be 
used if the ionic strength is near ~0.15 M. The pKa values of most common buffers, as a function of 
temperature and ionic strength, are encoded in the computer program used to design assay. Ordinarily, 
buffers are only recommended when pH adjustment cannot be precisely controlled by additions of 
standardized strong acid (e.g., HCl) or strong base (e.g., NaOH) titrant. The conversion of pH electrode 
reading from the “operational” scale to the concentration scale was effected by a four- parameter 
calibration procedure (Avdeef and Bucher, 1978; Avdeef, 2012). The experiments conducted here were 
guided by the above (“think-before-leap”) procedure, which we call the pH-Ramp Shake-Flask (pH-RSF) 
method.  
By contrast, traditional procedures are often trial-and-error in staging the collection of data. A 
series of buffers is selected to cover a range of pH suitable for the study. Phosphate, acetate, and borate 
buffers are commonly selected, often at 50-100 mM concentration. Solid compound is added 
incrementally to a solution buffered at a desired pH until an unspecified “excess” solid remains 
undissolved. In some cases, the procedure significantly alters the initial pH of the solution, requiring 
adjustments by additions of a strong acid or base. Sometimes, the buffer constituents form complexes 
with the drug (Shoghi et al., 2013), raising the equilibrium solubility. Also, buffer constituents may act as 
counterions leading to drug-salt precipitation, lowering the equilibrium solubility. Some buffers interfere 
with the analytical methods used to determine drug concentration (e.g., phosphate buffers in mass 
spectrometry). Assay details are often inadequately documented in traditional studies. 
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Tables S1-S3 given in Supplementary material summarize in sufficient detail the initial 
compositions and experimental conditions used in the solubility experiments. The temperature was kept 
constant at 251oC. Titrant solutions of HCl, NaOH, and H3PO4 were nominally 1 M, with precise 
concentrations determined potentiometrically.  
2.8.1 Sets 1 and 2 (high-to-low pH titration replicates) 
Titrations were performed in two directions: high-to-low pH values (Sets 1 and 2) and low-to-
high pH (Set 3). Sets 1 and 2: alkaline stock solutions were prepared by mixing 39.5 mL of 0.15 M 
NaH2PO4 (pH 4.34-4.37) and 10.5 mL standardized 1 M NaOH. DsHCl was added directly to the stock 
solutions: 0.41170 g (Set 1) and 0.41220 g (Set 2). Two-milliliter aliquots of the well-mixed drug-
containing saturated stock suspensions were placed into each of 13 vials. The initial pH in the vials was 
11.5-11.6. To each vial, a pre-calculated different volume of standardized 1 M HCl was added, ranging 
from 0 to 410 μL. The vials were capped and stirred for 6 h. After that, stirring was turned off, and 
sedimentation was allowed to take place for a further 18 h (“6+18 h” agitation-sedimentation 
equilibration sequence suggested in the “white paper”). All solids in the suspensions dissolved below 
pH 4. 
2.8.2 Set 3 (low-to-high pH titration) 
The Set 3 acidic stock solution was prepared by mixing 14.0 mL of 0.15 M NaH2PO4 (pH 4.45) 
and 1.00 mL standardized 1 M HCl. To the stock solution, 0.34370 g of DsHCl was added. A 1-mL 
aliquot of the well-mixed stock suspension was placed into each of 11 vials. To each vial, a different 
volume of standardized 1 M NaOH was added, ranging from 80 to 370 μL. The vials were capped and 
agitated as before (“6+18 h”). Below pH 4, no solids were found to precipitate in the vials.  
2.8.3 Set 4 (raised concentrations) 
Set 4 was designed to force precipitation in the pH 2-4 region. In the experiments, 0.900 mL of 
0.15 M NaH2PO4 solution was added to each of three vials containing 0.08650-0.08730 g DsHCl. The pH 
was adjusted using 1 M H3PO4 (Samples 1 and 2), NaOH (Sample 2), or HCl (Sample 3). The vials were 
capped and the solutions were allowed to equilibrate as before (“6+18 h”). Phases were separated by 
centrifugation (Samples 1 and 2) or filtration (Sample 3).  
2.8.4 Set 5 (phosphate-free titrations) 
A set without phosphate buffer was also designed (Set 5) in order to determine the drug-
hydrochloride solubility product in phosphate-free suspensions. Precisely 1.00 mL of 0.15 M NaCl was 
added to each of 7 vials containing accurately-weighed 0.04745-0.11205 g of DsHCl. The pH was 
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adjusted with standardized HCl (1.0211 M) and/or standardized NaOH (1.0215 M). Stirring was followed 
by sedimentation (“6+18 h”). Equilibrated pH values ranged from 1.31 to 10.04. Phases were separated 
by centrifugation.  
The detailed titration and solubility data are summarized in Tables S4-S8 (Supplementary 
Material). 
 
2.9 Preparation of samples for solid state characterization 
The above five titration sets did not produce sufficient amounts of solid for further analysis. So, 
in order to characterize the solid precipitate found in samples after equilibration, two series of additional 
experiments (below) were performed at pH expected to contain a specific single solid form of the drug, as 
suggested by preliminary analyses of the above five titration sets.  
2.9.1 Series 1 (Samples OM11-OM15, from suspensions containing both chloride and phosphate) 
Precisely 2.00 mL of 0.15 M NaH2PO4 solution were added to 5 vials containing accurately 
weighted 0.14-0.18 g of DsHCl. The total drug concentrations were about 2-3 times higher than those of 
Set 3. The pH was adjusted with 1 M HCl or NaOH. The vials were capped and allowed to equilibrate 
(“6+18 h”). Phases were separated by centrifugation, and each solid was further analyzed. The assay 
design details are summarized in Table S2 (Supplementary Material). 
2.9.2 Series 2 (Samples OM21-OM25, with one solid isolated from chloride-free suspensions)  
Sample OM21 was prepared in two steps. (a) To isolate the free base: precisely 2.00 mL of 
0.15 M NaH2PO4 solution were added to 0.125 g of DsHCl and mixed with 650 µL of 1 M NaOH. The 
sample was stirred for 6 h and left to sediment for 62 h. Despite longer sedimentation time at pH 11.6, 
precipitate was still oily. Phases were separated by centrifugation. Solid Ds (free base) was left to dry. 
(b) 900 µL of 0.15 M NaH2PO4 solution were added to 0.096 g of Ds precipitate from step (a) and mixed 
with 400 µL of 1 M H3PO4. The low-pH suspension was allowed to equilibrate (“6+18 h”). Phases were 
separated by centrifugation. The OM21 solid was washed with purified water and left to dry.  
Samples OM22-OM25 approximately paralleled the compositions in Set 3, except that 2-3 times 
higher drug concentrations were used. The specific quantities of reagents used are summarized in 
Table S3 (Supplementary Material). Equilibration followed the “6+18 h” procedure. The solids were 
separated from the suspensions by centrifugation, washed with purified water, and allowed to dry in air. 
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2.10 Refinement of intrinsic and salt solubility, aggregation and complexation constants 
The mathematical approach used in the pDISOL-X log S-pH simulation-refinement has been 
described by Völgyi et al. (2013). The program has been applied in several other recent studies (Avdeef, 
2014a, b; Butcher et al., 2015; Avdeef, 2015; Pobudkowska et al., 2016; Takács-Novák et al., 2017). 
Briefly, the data analysis method uses log S-pH as measured input data, with concentrations determined 
by a suitable analytical technique. The analytical concentrations of all added reagents are specified. 
“Excess drug added” is not sufficient information when drug-phosphate salts are suspected to precipitate 
during the titration, as emphasized in the “white paper.” The mass action algorithm considers the 
contribution of all species proposed to be present in solution, including all buffer, counterion, and inert 
electrolyte components. The approach does not assume the validity of the Henderson-Hasselbalch 
relationship, nor does it depend on any explicitly derived extensions of the HH equations. The mass 
action algorithm derives its own implicit equations internally, given any practical number of hypothesized 
equilibrium reactions and the corresponding estimated constants, which are subsequently refined by 
weighted nonlinear least-squares regression. The presence of specific drug-phosphate precipitates can be 
tested. The program calculates the distribution of species consequent to a sequence of additions of 
standardized strong-acid titrant HCl (or ionizable-acid titrants such as H3PO4) to simulate the suspension 
pH-speciation down to pH ~ 0, the staging point for the subsequent steps. Then, a sequence of 
perturbations with standardized strong-base titrant (e.g., NaOH) is simulated, and solubility calculated at 
each point, until pH ~ 13 is reached. The ionic strength, I, is rigorously calculated at each step, and the 
pKa value (as well as solubility products, aggregation and complexation constants), along with pH 
electrode calibration constants, are accordingly adjusted for changes from the benchmark level of 0.15 M 
(Avdeef, 1992, 2012).   
At the end of the pH-speciation simulation, the calculated log S- pH curve is compared to 
measured log S vs. pH. A user-supervised log S-weighted nonlinear least squares refinement commences 
to refine the user-proposed equilibrium model. The underlying differential equations are solved using 
analytical expressions encoded in the program. The process is repeated until the differences between 
calculated and measured log S values reach a minimum. Different model species are tested to make 
further improvements in the fit. 
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3. Results and discussion  
 
3.1 Summary of the interlaboratory consensus recommendations applied in this study  
The “white paper” commentary (Avdeef et al., 2016) reviewed a number of factors that can affect 
the quality of equilibrium solubility measurement as a function of pH of sparingly-soluble druglike 
molecules. It was asserted that the traditional shake-flask method is the “gold standard,” although other 
validated methods with well-defined protocols could also be used. It was stressed that independently-
determined pKa values of the drug be used in the analysis of the log S-pH data. The importance of solid 
state characterization was also stressed, citing several case studies of polymorphic transformations. The 
complexity on the solution side of solubility-pH measurement was illustrated with several case studies, 
where aggregates (micellar and sub-micellar) and drug-buffer complexes appeared to form. The 
importance of measuring the final pH (not that of the starting buffer) accurately in buffered and 
unbuffered solutions was discussed at length. Methods and pitfalls of separating solid from saturated 
solutions were critically discussed. The reporting of the temperature, ionic strength, buffer compositions, 
and other experimental detail was encouraged. When such “good practices” could be followed, it was 
expected that high quality results in solubility measurement could be achieved. 
 
3.2 pKa determination from solubility-pH data 
 The independently measured pKa of desipramine, 10.28 ± 0.03 (26
o
C, Iref 0.15 M), verified by 
three different potentiometric procedures (Avdeef, 2012), was used in the study here. The apparent 
constant determined from the current log S-pH data led to values as high as 10.44. The significant 
difference between the two values led us to suspect that either aggregation or complexation reactions may 
be present in the phosphate-containing alkaline solutions. 
 
3.3 Solubility analysis 
3.3.1 Data 
The solubility-pH profiles of DsHCl in buffer-free and phosphate buffer, designed with the pH-
RSF method, are shown in Figure 1. The reported solubility values are based on molarity units. The 
detailed titration (Vtitrant- pH) and solubility (log S-pH) data are presented in Tables S4-S10 
(Supplementary Material). 
Sets 1 and 2 (Figure 1a) are duplicate experiments, where alkaline suspensions (pH 11.6) 
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containing [Ds]tot = [Cl]tot = 27 mM and [PO4]tot = 119 mM, were acidified with HCl. Set 3 (Figure 1b) 
represents the titration in the opposite direction, where acidified (pH 1.90) suspensions, with somewhat 
higher concentrations [Ds]tot = 76 mM, [Cl]tot = 142 mM, and [PO4]tot = 140 mM, were titrated with 
NaOH up to pH 11.6. In the three sets, solutions below pH 3.9 did not achieve saturation.  
Set 4 (upper Figure 1c) was designed in order to get solid precipitate in pH region below 4. 
Higher drug concentrations were used: [Ds]tot = [Cl]tot = 320 and [PO4]tot = 150 mM. The number of 
analysed samples in this pH region was limited due to excessive amounts of DsHCl required to reach 
saturation.  
Due to the possibility of co-precipitation of chloride and phosphate drug salts at low pH 
(Völgyi et al., 2013), the phosphate-free Set 5 (lower Figure 1c) experiments were designed to determine 
the Ksp
DsH.Cl
= [DsH
+
][Cl
-
], without interference from phosphate. [Ds]tot ranged from 145 to 369 mM and 
[Cl]tot from 145 to 402 mM (cf., Table S8).  
Series 1 and 2 measurements (cf., Tables S2, S3, S9, and S10) were designed in order to get 
enough precipitate for solid state analysis.  
3.3.2 Refinement of constants 
 Whereas the solubility product is an equilibrium constant, the solubility of a charged drug is 
variable, whose value depends on the concentration product of two independent reactants (drug and 
counterion). In the pH domain where the drug is charged, its solubility can be varied simply by selecting 
different concentrations of the counterion. The “common ion” effect of a drug hydrochloride salt is a 
good example of this phenomenon: the solubility of a positively-charged drug decreases as HCl is used to 
lower the pH (which increases the chloride counterion concentration).   
The sample points from each of Sets 1-5 were designed (pH-RSF) specifically to be fit to a single 
log S-pH curve across a range of pH values, generally requiring that for each sample point, the total drug 
concentration (after correction for dilution) to be essentially the same, and that the drug:counterion ratio 
to be variable only when the titrant includes the counterion as a constituent. On the other hand, the Series 
1 and 2 sets (Samples OM11-15 and OM21-25) were less constrained as they were designed to generate 
sufficient quantities of precipitate for solid state characterizations, with different samples possibly 
associated with different members of a conditional family of log S-pH curves. 
The determination of equilibrium constants began with Sets 1 and 2 treated separately. Since 
nearly the same constants were determined by weighted nonlinear regression, the two sets were merged, 
and a combined analysis was performed. The refined constants are summarized in Table 1 and the plot of 
the fitted curve is shown in Figure 1a by the solid curve. The dashed curve in the figure was calculated 
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with the Henderson-Hasselbalch (HH) equation, using the independently-determined pKa 10.28. It is 
evident in Figure 1a for pH > pHmax (a conditional constant) that the points do not fall on the HH curve. 
In certain cases, the pKa value can be determined from the solubility data. However, in our case the 
resultant value was significantly higher than the independently-determined pKa. In complicated systems, 
it is not recommended that the pKa value be determined from log S-pH data (Butcher et al., 2015; Völgyi 
et al., 2010). At least two possible explanations for the difference could be proposed here: (a) drug self-
aggregation (e.g., dimer formation), or (b) drug-buffer complexation (e.g., Ds-phosphate anionic 
complexes). Since the analysis of Set 5 (lower Figure 1c) did not indicate deviations from the HH curve 
in the alkaline solution, drug-phosphate complexation (b) was favored over drug self-aggregation (a). The 
data were tested against several possible complexation reactions. The simplest which rationalized the data 
was based on the reaction involving the formation of a monoanionic complex, 
      Ds + DsH
+
 + HPO4
2-
      Ds(DsH+)HPO4
2-
      (1a)  
with the corresponding constant 
      log K221 = [Ds(DsH
+
)HPO4
2-
] / [Ds][DsH
+
][HPO4
2-
 ]     (1b) 
where the subscript 221 refers to the (Ds,H,PO4) stoichiometry of the formed species. The refined value is 
log K221 = 4.58 ± 0.10 (Table 1). The pH 4-9 domain could be rationalized by the formation of the 2:1 
drug salt, 
        (DsH
+
)2HPO4
2-
(s)     2 DsH+ + HPO4
2-
            (2a)  
with the corresponding solubility product, 
      log Ksp
2:1
 = [DsH
+
]
2
[HPO4
2-
 ]         (2b) 
where the superscript 2:1 refers to the drug:phosphate stoichiometry of the formed solid. The refined 
value is log Ksp
2:1
 = -7.38 ± 0.01 (Table 1). 
 Since the solutions in Set 1 and 2 contained chloride, it was necessary to verify that the solubility 
product was due solely to reaction (2a). Set 5, which contained no phosphate, indicated that the drug-
chloride solubility product is log Ksp
DsH.Cl 
= -2.19 ± 0.03 (Table 1). When this value was included in the 
equilibrium model for Sets 1 and 2, along with the other constants, it was found that the solubility product 
for the hydrochloride salt was not exceeded, so no hydrochloride salt co-precipitate was expected at the 
concentration levels in Sets 1 and 2 (pH > 4). 
 The intrinsic solubility, log S0 = -3.85, was entered in the Sets 1 and 2 refinement as a fixed 
contribution, based on the value refined with the Set 5 data, which showed no deviations from the HH 
curve. It would be challenging to refine both the log S0 and the log K221 simultaneously in Sets 1 and 2, 
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since the two constants are co-dependent. 
 Since the tendency to form a supersaturated solution (often near pHmax) depends on the solid state 
of the starting materials (e.g., Zografi and Zarenda, 1966), Set 3 was devised to be a titration going from 
low-to-high pH, in the direction opposite of that of Sets 1 and 2. Figure 1b shows the best-fit results of 
the analysis. In the alkaline solution of Set 3, there is comparable deviation from the HH curve, as in the 
case of Sets 1 and 2. Table 1 lists the refined constants. The salt solubility was somewhat elevated in 
Set 3, compared to that in Sets 1 and 2. The complexation constants were slightly different, but not 
significantly, given the standard deviations, SD= 0.10, from the refinement in both cases. The measured 
solubility values of samples OM14, OM15, OM24 and OM25 were merged into the Set 3 calculations, 
since these OM samples were at pH > pHmax (cf., Figure 1b), where salt precipitation is minimal. The 
OM samples were also consistent with complexation taking place.  
 As evident from the above discussion, the phosphate-free Set 5 data analysis played a key role in 
rationalizing the phosphate-containing model based on the Sets 1-3 data. Set 5 data were taken to be an 
accurate basis for the determination of the intrinsic solubility of desipramine: log S0 = -3.85 ± 0.04, in the 
apparent absence of interference due to complex formation. 
Set 4 (upper curve in Figure 1c) also played an important role in the evolution of the overall 
equilibrium model. The low pH and the high drug concentrations suggested that both DsH.Cl and 
DsH.H2PO4 could co-precipitate, since the log Ksp, -2.19 (from Set 5) and -2.55 (from Sample OM21), 
respectively, were comparable. However, the inclusion of both constants in the data analysis could not 
explain the upper curve in Figure 1c. It was only after the formation of a monocationic complex was 
included that the fit was possible.   
        2 DsH
+
 + H2PO4
-
      (DsH+)2H2PO4
-
        (3a)  
 with the corresponding constant 
      log K241 = [(DsH
+
)2H2PO4
- 
] / [DsH
+
]
2
[H2PO4
-
 ]        (3b) 
The refined value is log K241 = 3.96 ± 0.02 (Table 1). 
 A further unexpected subtlety was revealed (supported by DSC measurement below): even 
though the Ksp of DsH.H2PO4(s) was lower than that of DsH.Cl(s), under the concentrations in Set 4 
samples, it was the hydrochloride salt that precipitated. The solubility product of the phosphate salt was 
below the equilibrium constant value, partly because the phosphate was preferentially tied up with the 
water-soluble monocationic complex. The discussion in Sec. 3.4.2 further elaborates on this. 
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3.4 Desipramine solid state characterizations 
3.4.1 Elemental analysis 
Elemental analysis (EA) results are shown in Tables 2 and 3. The CHN analysis of the reference 
(Sigma-Aldrich) DsH.Cl(s) solid was 70.89% C, 7.46% H, 9.20% N. Evidently, the solids isolated from 
Set 5 (phosphate-free) from pH 1.3-7.5 suspensions are likely the anhydrous DsH.Cl(s) (Table 2). 
The solids isolated from phosphate-containing suspensions (Table 3) have less obvious identities 
based on the elemental analyses. As a guide, the comment column in Table 3 lists the species suggested 
from the pH-specific PXRD analyses (below). Based on theoretically-calculated CHN percentages, most 
of the samples appear to be extensively hydrated (or not adequately dried). Sample OM15 (pH 11.1) is 
compatible with Ds.2H2O, while OM14 (pH 9.57) and OM24 (pH 9.44) are more concordant with 
Ds.6H2O. The samples in the pH 3.84-8.55 interval are compatible with hydrates of the 2:1 phosphate 
salt: from 4-hydrate (OM12) to 16-hydrate (OM23). EA of OM21 is consistent with a dihydrate of the 1:1 
phosphate salt. However, the TGA data (Figure 2) indicates lower levels of hydration than that of EA, 
although the trends between the two types of assessments are similar. The equilibrium analysis of the log 
S-pH data, consistent with the constants reported in Table 1, suggests that at pH 9.44 and 9.58, the only 
solid present in the suspension is the free base. The above suggests that the phosphate salts may have a 
high tendency to precipitate in mostly hydrated forms. A well-known characteristic of drug-free sodium 
phosphate salts to be highly hydrated (up to dodecahydrate) may have spilled over into drug-phosphate 
salts. 
3.4.2 Solid state analyses of precipitates obtained at different pH 
Results of DSC analyses of precipitates as well as the neat DsHCl (Sigma-Aldrich) are shown in 
Figure 3. All samples except for DsHCl and the precipitate obtained at pH 2.09 from the chloride-free 
solution showed broad endotherms at around 100-120ᵒC in DSC scans (OM12, OM13, OM14, OM23, 
OM24, OM25, OM15, and OM21). The results of thermogravimetric analyses (TGA) presented in Figure 
2 show that the endotherms observed at 100-120ᵒC are apparently due to the formation of hydrates since 
there were weight losses in the approximately similar temperature; the onset of weight loss in TGA scans 
was at somewhat lower temperature due to the effect of nitrogen purging during the experiments. The 
presence of endotherms in the DSC scans at around 100ᵒC and the weight loss in the TGA scans at 
temperatures close to 100ᵒC indicate that any moisture associated with the solid is bound, possibly, as 
part of the crystal lattice or embedded deep into crystal channels (cf., Table 3). The PXRD patterns of the 
precipitates presented in Figure 4 indicate that all the precipitates are also crystalline, although an 
amorphous halo was observed in PXRD patterns in one of the two precipitates isolated at pH 11.10. As 
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shown by the DSC heat-cool-heat cycle of a representative sample (OM13) in Figure 3d that once a 
sample is heated beyond its dehydration endotherm, it converts to the amorphous form unless there was a 
separate endotherm originally present in the sample at higher temperature (see Figures 3a and 3b for 
sample OM21). 
Although the crystalline nature of the precipitates obtained from phosphate buffered solutions at 
different pH cannot be readily distinguished by the DSC scans as most of them have similar dehydration 
endotherms at around 100ᵒC, distinct differences exist in their PXRD patterns. As shown in Figure 4, 
there are three different PXRD patterns at (a) pH 11.1, (b) pH 9.44-7.41 and (c) pH 2.13; any minor 
difference observed in the range of pH 9.44 to 7.41 could be due to the difference in hydration of the 
crystals. These three distinctly different PXRD patterns may be attributed to the existence of, 
respectively, (a) Ds (free base), (b) (DsH
+
)2HPO4
2-
(s) and (c) (DsH
+
)H2PO4
-
(s). The formation of these 
species agree with the ionization of phosphoric acid, which has pKa values of 1.92, 6.70, and 11.72 (25
o
C, 
I = 0.15 M). It is evident from Figure 3a that the free base and (DsH
+
)2HPO4
2-
(s) exist in crystalline states 
only as hydrates and they convert to the amorphous phase after dehydration. On the other hand, although 
a hydrate, (DsH
+
)H2PO4
-
(s) (pH 2.13) maintains its crystallinity after dehydration (Figure 3b). Since the 
solids remain in equilibrium with water during the determination of pH versus solubility profile, these 
results demonstrate that the solids always remain in the crystalline state during solubility studies.  
In Figure 3a, sample OM11 (“phosphate-poor”) shows an endotherm that matches that of the 
reference DsHCl (Sigma-Aldrich) at 217°C. It may appear surprising that OM11, consisting of 0.14 M 
total phosphate concentration (Table S2), does not form a phosphate precipitate since Ksp
1:1
 < Ksp
DsH.Cl
 
(Table 1).  There is clearly ample amount of available chloride (0.29 M) to form the drug-chloride 
precipitate, given that the product of [DsH
+
] and [Cl
-
] exceeds the Ksp
DsH.Cl
 value.  At pH 2.09, most of the 
available monohydrogen phosphate is tied up in the cationic drug-phosphate complex, [(DsH
+
)2.H2PO4
-
], 
whose concentrations is calculated to be 0.11 M. There is simply not enough uncomplexed monohydrogen 
phosphate available to form the drug-phosphate salt under these conditions. The DSC confirms the above 
equilibrium analysis. 
Sample OM21 (“chloride-free” in Figure 3a) at pH 2.13 was prepared from the desipramine free 
base, so the endotherm at 175°C (the second dip in the DSC scan in Figure 3a) is likely that of the 
melting point of the 1:1 desipramine phosphate salt. Figure 3b shows the heat-cool-heat cycle, where the 
first endotherm disappears, and a sharpened dip at the higher temperature persists, suggesting a 
dehydration process of the 1:1 phosphate salt. 
In samples OM12 and OM22 (pH 3.9), the monoanionic phosphate is near that of the total 
phosphate concentration, so the expected solid should not contain any chloride salt, based on the 
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equilibrium analysis. The transition pH from (DsH).H2PO4(s) to (DsH)2.HPO4(s) is estimated to be at 
pHmax between 4.0 (Figures 1a, and 1b) and 4.7 (upper curve in Figure 1c), depending on total 
concentrations used. The DSC scan of one of these samples isolated at pH 3.9 (OM12) in Figure 3a show 
only the dehydration endotherm around 100°C indicating hydrate formation, and when the 
heat-cool-cycle was conducted, the material converted to amorphous upon dehydration (Figure 3c). In 
this respect, the sample OM12 behaves like OM13 (pH 7.4) (Figure 3d), which has been attributed to the 
formation of a 2:1 phosphate salt. Since the DSC scan of OM12 differs from that of OM21, which, as 
mentioned later, is considered to be a 1:1 phosphate salt, it is very likely that a 2:1 phosphate salt was 
formed from the buffered solution at pH 3.9. The similarity in crystal patterns between Samples OM12 
and OM13 could, however, not be confirmed by PXRD as the isolated sample of OM12 was insufficient 
to run a PXRD experiment.  
It may be noted in Figure 4 that PXRD patterns of two precipitates isolated at pH 11.1 differ 
considerably with respect to their degree of crystallinity, one showing larger amorphous halo than the 
other. Although we are not aware of any previous study of the solid state properties of desipramine free 
base, they could be similar to physicochemical attributes of a related compound, chlorpromazine free 
base, which is known to be amorphous in the solid state (Zografi and Zarenda, 1966). It is evident in 
Figure 4 that the material isolated from aqueous medium at pH 11.1 is a crystalline hydrate that can 
readily convert to the amorphous form during preparation (hence the difference in amorphous halo) or 
upon heating. It may also be noted from the TGA scans in Figure 2 that the free base is volatile as the 
sample continues losing weight after dehydration. 
In contrast to precipitates isolated from the phosphate-buffered solutions, the sample OM11 
(pH 2.09) that was isolated from the phosphate-poor solution showed a melting endotherm only at 217
o
C, 
indicative of the formation of anhydrous DsH.Cl, which is precisely what was predicted from the 
refinement of log S-pH data in Set 4. On the other hand, the chloride-free OM21 (pH 2.13) showed two 
melting endotherms; one around 100ᵒC and other around 175ᵒC. This is indicative of the 1:1 phosphate 
salt showing a dehydration pattern. Once the sample was subjected to heat-cool-reheat cycle by first 
heating the sample to 120ᵒC for dehydration, the first endotherm disappears and the second endotherm 
due to the melting of the sample becomes even sharper, indicating the high crystallinity of the 1:1 drug-
phosphate salt (Figure 3b). 
The elemental analysis of phosphate containing preparations shown in Table 3 and the TGA 
scans of the same in Figure 2 show that there were different amounts of water present in different 
samples. As mentioned under Materials and methods, the samples were only air-dried before analysis. 
No further treatment was done to maintain the sample closely similar to what were present in equilibria 
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with aqueous media. However, it is possible that all samples did not dry to the same extent during air-
drying depending on how much solid was present in a wet mass and how long it was dried. Although the 
difference in water content did not change the nature of DSC scans and the powder X-ray patterns, it 
could be responsible for the observed difference in moisture content in elemental analysis and TGA scans. 
To investigate this possibility, we subjected samples OM13 (7.41) and OM23 (pH 8.03) that showed, 
respectively, 5.3 and 25.7% weight loss, to identical humidity conditions of 50% RH at 25°C by using a 
VTI SA dynamic vapor sorption instrument (TA Instruments, Wilmington, DE) for equilibration until 
there was no weight gain or loss due to moisture sorption or desorption. As shown in Figure S1 
(Supplementary Materials), there was ~2% moisture sorption by OM13 (Figure S1c), while there was a 
moisture desorption of ~17% with OM23 (Figures S1a). TGA scans of the samples equilibrated at 
25°C/50% RH showed the weight loss of both samples were similar and in the range of 5-6% (Figures 
S1b and S1d), corresponding to approximately 2 moles of water. Thus, it is evident that the difference in 
moisture contents observed in Table 3 and Figure 2 could be due to the difference in the extent of drying. 
However, DSC scans and PXRD patterns of various samples show that any difference in moisture content 
did not change crystalline nature of the precipitates formed in equilibria with phosphate buffers, and, as 
evident from the representative examples in Figures 3c and 3d, irrespective of the extent of hydration, 
any (DsH
+
)2HPO4
2-
hydrates formed may convert to amorphous form upon dehydration by heating. 
 
4. Conclusions 
The critical analysis of the desipramine system in saturated aqueous saline phosphate buffer 
suspensions revealed complexity not addressed previously.  
While most pH versus solubility studies of free bases are conducted by adjusting pH by using a 
monoprotic acid like HCl, a triprotic acid H3PO4 was used in the present study to determine the 
solubility-pH profile of 1:1 desipramine phosphate salt. The results are compared with the solubility-pH 
profile of the 1:1 desipramine chloride salt determined in a phosphate-free medium. The results showed 
the complex nature of the solid phase formed under different pH conditions in the phosphate buffer. At 
pH 11, the crystalline hydrate of the desipramine free base was formed and existed as the solid phase. At 
lower pH in the range of 4 to 9.5, the solid species in equilibria with solutions was crystalline 
(DsH
+
)2HPO4
2-
(s) hydrate, and at the lower pH of 2.1, the solid phase was the hydrated (DsH
+
)H2PO4
-
(s). 
These three solid phases were distinct from each other; while both the crystalline free base and the 
(DsH
+
)2HPO4
2-
hydrates converted to the amorphous phase upon dehydration by heating, the hydrated 
(DsH
+
)H2PO4
-
(s) remained crystalline upon dehydration. The different solid phases present in equilibia 
with solutions influenced solubility vs. pH of desipramine hydrochloride in phosphate buffers. They are 
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also responsible for the difference between solubility profile of desipramine hydrochloride in phosphate 
buffers from that in the phosphate-free medium.    
Given the solid state characterization in the present study, it is now clear that the earlier 
interpretation by Avdeef (2014b) of the desipramine hydrochloride behavior in 0.15 M phosphate buffer 
(Bergström et al., 2004) was based on an invalid assumption that the precipitate in the pH 7-9 region was 
the desipramine free base. It is now clear that the free base exists only above pH 9.5 in the phosphate 
buffer. 
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Appendix - Example of an explicit mass action model  
The following equilibrium reactions are characteristic of much of the titration data in the study. 
As a generalized example of a monoprotic weak base, B, a saturated solution can be defined by the 
equations (4 homogeneous and 4 heterogeneous phases) and the corresponding constants: 
 
BH
+
    H+ + B      Ka = [H
+
][B] / [BH
+ 
]   (A.1)  
H3PO4        H
+
 + H2PO4
-
    Ka1 
buf
 = [H
+
] [H2PO4
- 
] / [H3PO4
 
]  (A.2)  
H2PO4
-
        H+ + HPO4
2-    Ka2 
buf
 = [H
+
] [HPO4
2- 
] / [H2PO4
- 
]  (A.3)  
HPO4
2-        H+ + PO4
3-    Ka3
buf
 = [H
+
] [PO4
3- 
] / [HPO4
2- 
]   (A.4)  
B(s)     B      S0 = [B]     (A.5)  
(BH
+
)2·HPO4
2-
(s)          2 BH+ + HPO4
2-
  Ksp
2:1
 = [BH
+
]
2 
[HPO4
2-
 ]  (A.6) 
BH
+
·H2PO4
-
(s)           BH+ + H2PO4
-
   Ksp
 1:1 
= [BH
+
] [H2PO4
- 
]   (A.7) 
BH
+
·Cl
-
(s)           BH+ + Cl-    Ksp
BH.Cl
 = [BH
+
] [Cl
- 
]   (A.8) 
 
If the concentration of the drug is kept below its intrinsic solubility, then usually Eqs. (A.5)-(A.8) 
need not be considered. In such a homogeneous solution, the three independent reactants are B, PO4
3-
 and 
H
+
. The corresponding mass balance equations may be stated as 
 
[B]tot     = [B] + [BH
+
]         (A.9) 
[PO4]tot = [PO4
3- 
] + [HPO4
2- 
] + [H2PO4
- 
] + [H3PO4 ]     (A.10) 
[H]tot       = [H
+
] – Kw / [H
+
] + [BH
+
] + [HPO4
2- 
] + 2[H2PO4
- 
] + 3[H3PO4 ]   (A.11) 
 
Kw is the ionization constant of water. On substituting the equilibrium quotients from Eqs. (A.1)-(A.4) 
into the mass balance equations, one gets three polynomials as a function of the three reactants (B, PO4
3-
, 
H
+
) and the equilibrium constants Ka, Ka1
buf
, Ka2
buf
, Ka
buf
, and Kw. 
 
      [B]tot     = [B] + [B][H
+
]/Ka         (A.12) 
      [PO4]tot = [PO4
3- 
] {1 + [H
+
] / Ka3
buf
 + [H
+
]
2
 / Ka3
buf∙Ka2 
buf
 + [H
+
]
3
 / Ka3
buf∙Ka2 
buf∙Ka1 
buf
 }    (A.13) 
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      [H]tot = [H
+
] – Kw / [H
+
] + [B][H
+
]/Ka  
     + [PO4
3- 
] { [H
+
] / Ka3
buf
 + 2 [H
+
]
2
 / Ka3
buf∙Ka2 
buf
 + 3 [H
+
]
3
 / Ka3
buf∙Ka2 
buf∙Ka1 
buf
 }    (A.14) 
 
The [B], [PO4
3-
], and [H
+
] roots of the above equations are solved using standard mathematical techniques 
(Avdeef, 2012). Kw and the ionization constants are generally provided as fixed parameters in the 
calculation. Those of standard buffers are coded internally, adjusted to the assay conditions of 
temperature and ionic strength. 
 If the concentration of the drug is above the intrinsic solubility and the pH of the solution is very 
alkaline, then Eq. (A.5) needs to be introduced into the calculation. The calculation becomes more 
complex, since one of the reactants loses its independence, and needs to be expressed in terms of the 
remaining reactants. One less mass balance equation needs to be explicitly considered in the solution for 
the roots. This procedure has been described in detail elsewhere (Avdeef, 2017).   
If the solubility measurements are carried out in an acidic solution, with enough compound added 
that the solubility products [BH
+
]
2 
[HPO4
2-
 ] and/or [BH
+
] [H2PO4
- 
] are exceeded, then Eqs. (A.6) and 
(A.7) would need to be considered in the further more complicated procedure. At very low pH, the 
possible role of the drug-chloride precipitate (Eq. A.8) is tested for. The program automatically checks to 
see if the solubility products are exceeded at a particular pH, and appropriate constraints are automatically 
applied. At any given pH, the program tests for any violations of the Gibbs Phase Rule. All such 
complicated equations are sorted out implicitly in the mass action algorithm of pDISOL-X, and their 
explicit derivations are not necessary for the computation.   
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Figure Captions 
 
Figure 1 – Solubility-pH profiles for the desipramine at 25oC. The dashed curves were calculated with the 
Henderson-Hasselbalch equation, using the independently-determined pKa = 10.28 and the intrinsic 
solubility log S0 = -3.85, determined from Set 5 (cf., Table 4). The solid lines are best-fit refinement curves 
through the measured log S-pH points. (a) Sets 1 and 2 are replicate titrations, where alkaline suspensions 
(pH 11.6) containing [Ds]tot = [Cl]tot = 27 mM and [PO4]tot = 119 mM, were acidified with HCl. No 
precipitate was observed below pH 4. (b) Set 3 represents the titration in the opposite direction, where 
acidified (pH 1.90) solutions, with slightly higher concentrations [Ds]tot = 76 mM, [Cl]tot = 142 mM, and 
[PO4]tot = 140 mM, were titrated with NaOH up to pH 11.6. Precipitate appeared only above pH 4. (c) Set 
4 (upper solid curve) was designed in order to induce precipitation of solid for pH < 4. Higher drug 
concentrations were used: [Ds]tot = [Cl]tot = 320 mM and [PO4]tot = 150 mM. Set 5 (lower curve) consisted 
of buffer-free 0.15 M NaCl suspensions of DsHCl, with HCl/NaOH to adjust the pH. The data in Set 5 
were used to determine the drug-hydrochloride solubility product in phosphate-free suspensions, and to 
determine the intrinsic solubility, log S0, in the absence of phosphate complexation. 
Figure 2 – Thermogravimetric analysis (TGA) scans of precipitates obtained at different pH. Samples 
were used ‘as is’ and the moisture loss could vary depending on how the samples were isolated and dried. 
While the weight loss equilibrated after dehydration of samples obtained at pH 2.13, 7.41, and 8.03 
(relatively flat region >100°C), the weight loss continued in pH 9.44, 9.47 and 11.10 samples, possibly 
due to both dehydration and sublimation of materials. Temperatures at relatively flat regions were used to 
calculate weight losses in different scans. 
Figure 3 – Differential scanning calorimetric ( SC) scans of different precipitates isolated during the 
determination of solubility-pH profile of desipramine HCl. (a) DSC scans of precipitates and the neat 
desipramine HCl (‘as is’) as a function of temperature, indication dehydration endotherms around 100oC and 
melting endotherms at higher temperature; (b) heat-cool-heat run cycles of precipitate isolated at pH 2.13 
(OM21), indicating dehydration in cycle 1 and only the melting peak and no dehydration during reheating in 
cycle 3; (c) heat-cool-heat run cycles of precipitate isolated at pH 3.86 (OM12), indicating dehydration in 
cycle 1 and no dehydration or melting peaks during reheating in cycle 3; and (d) heat-cool-heat run cycles 
of precipitate isolated at pH 7.41 (OM13), indicating dehydration in cycle 1 and no dehydration or 
melting peaks during reheating in cycle 3.   
Figure 4 – Powder X-ray diffraction (PXRD) patterns of precipitates isolated at different pH. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
25 
 
Table 1. Refinement of desipramine equilibrium constants 
a
 
Set 
and/or 
Sampl
e 
logS
0 
SD 
log Ksp
1:1 
[DsH+][H2PO
4
-] 
SD 
log Ksp
2:1 
[DsH+]2[HPO
4
2-] 
SD 
log K241 
[(DsH+)2.H2P
O4
-] 
SD 
log K221 
[DsH+.Ds.HPO
4
2-] 
SD 
log Ksp
1:1 
[DsH+][C
l-] 
SD 
pHrang
e 
pHma
x 
Iavg
b 
GOF
c 
N 
c 
1 & 2 
-
3.85 
n.v.   -7.38 
0.0
1 
  4.58 
0.1
0 
  
4.4-
11.6 
9.5 
0.4
1 
0.51 
2
6 
OM21   -2.55 
n.d.
d 
-7.38 n.r.e       2.1 3.3 
0.1
5 
n.d.d 1 
3 & 
OM14
, 
OM15
, 
OM24
, 
OM25 
-
3.85 
n.v.   -7.06 
0.0
3 
  4.80 
0.1
0 
  
4.0-
11.5 
9.3 
0.4
1 
0.67 
1
5 
OM23   -2.55 n.r.
e -7.27 
n.d.
d 
      8.0 4.9 
0.2
8 
n.d.d 1 
4 & 
OM22 
  -2.55 n.r.e -7.06 n.r.e 3.96 
0.0
2 
  -2.19 
n.r.
e 
2.0-
3.8 
4.7 
0.3
0 
0.37 4 
5 
-
3.85 
0.0
4 
        -2.19 
0.0
3 
1.3-
10.0 
8.0 
0.2
5 
0.50 7 
a
25
o
C. Ref. ionic str.=0.15 M. pKa=10.28 in all cases. Max. buffer capacity=49 to 137 mM/pH in the data. 
Determined constant underlined. See text for other terms. 
b
Average ionic strength (M). 
c
Goodness-of-fit={1/(N-Nr) Σ [(log S
obs
-log S
calc
)/SD(log S)]
2
}
1/2
: SD(log S)=0.10 assumed for all points; N=no. of 
log S points used; Nr=no. of varied parameters. 
d
n.d.=not defined, since N=1. 
e
n.r.=included in the model, but not refined. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
26 
 
 
Table 2. Elemental analyses of solids isolated from Set 5 (phosphate-free) 
Sample pH %C %H %N 
1 1.31 70.18 7.25 9.12 
2 2.38 70.62 7.64 9.34 
3 3.02 70.53 7.22 9.25 
4 4.93 70.96 7.29 9.21 
5
a 
7.59 70.85 7.30 9.18 
  a Suspension appeared to be supersaturated. 
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Table 3. Elemental analyses of solids isolated from phosphate-containing preparations 
Sample pH %C %H %N Comment
a
 x.H2O(EA)
b
 x.H2O(TGA)
c
 
OM11 2.09 76.64 10.36 9.88    
OM21
d
 2.13 54.65 7.25 7.03 DsH.H2PO4(s) 2 0.7 
OM22 3.84 57.51 6.95 7.36  7  
OM12 3.86 62.12 8.13 7.97  4  
2 (Set 2) 5.36 60.94 7.52 8.16  5  
OM13 7.41 60.41 7.80 7.82 (DsH)2.HPO4(s) 5 2 
5 (Set 2) 7.50 60.78 7.36 7.87  5  
OM23 8.03 46.80 8.44 6.01 (DsH)2.HPO4(s) 16 9 
6 (Set 1) 8.55 58.70 7.20 7.73  7  
OM24 9.44 58.49 8.37 7.66 Ds(s) 6 0.6 
OM14 9.57 56.64 6.46 7.29 Ds(s) 6 0.7 
OM15 11.10 72.47 9.09 9.36 Ds(s)
e
 2 0.5 
 a Species suggested from PXRD, accounting for the solution pH from which the solid was isolated (cf., Figure 4). 
 b Estimated number of water molecules in analyzed solid, based on theoretical CHN values. 
 c Estimated number of water molecules in analyzed solid, based on TGA analysis (cf., Figure 2).   
 d Chloride-free. 
   
e
 Mixture of crystalline and amorphous material. 
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